Lexicon Pharmaceuticals Inc
Suletud
SektorTervishoid
1.92 1.05
Ülevaade
Aktsiahinna muutus
24h
Min
1.9100000000000001
Max
1.98
Sissetulek | 14M -1M |
|---|---|
Müük | 16M 21M |
Aktsiakasum | -0.003 |
Kasumimarginaal | -4.943 |
Töötajad | 81 |
EBITDA | 14M -996K |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +161.98% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 125M 835M |
|---|---|
Eelmine avamishind | 0.87 |
Eelmine sulgemishind | 1.92 |
Uudiste sentiment
By Acuity
30%
70%
77 / 342 Pingereas Healthcare
Lexicon Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.